<DOC>
	<DOCNO>NCT00670631</DOCNO>
	<brief_summary>The two objective study : - To increase 2-year event-free survival 55 % , establish Total Therapy II ( UARK 98-026 ) , 75 % myeloma patient cytogenetic abnormality , 80 % , establish Total Therapy II regimen , 95 % myeloma patient without cytogenetic abnormality . - To determine whether bortezomib , thalidomide , dexamethasone safely incorporate transplant 1 establish pre-transplant regimen high-dose melphalan ( use Total Therapy II ) whether Velcade gemcitabine safely add transplant 2 high-dose chemotherapy regimen combination melphalan BCNU .</brief_summary>
	<brief_title>Tandem Transplantation Multiple Myeloma ( MM ) Patients With &lt; 12 Months Prior Treatment</brief_title>
	<detailed_description>This study target towards patient diagnose Multiple Myeloma prior autologous allogeneic transplant . Furthermore , 12 month prior treatment allow patient population . The study schema consist one round induction chemotherapy , two transplant , one round consolidation chemotherapy , two year maintenance treatment . This study design differs historical predecessor follow manner : - In contrast Total Therapy II III , allow enrollment patient one cycle one month treatment prior enrollment , propose study allow enrollment patient 12 month prior treatment . No statistically significant difference outcome patient one cycle precede therapy 12 month prior therapy . This allow enrollment significantly myeloma patient . - Induction therapy reduce single cycle . - Bortezomib thalidomide add transplant regimen . - BCNU add second transplant high dose melphalan . - Gemcitabine add second transplant regimen . - Consolidation treatment reduce single cycle . - The first year maintenance bortezomib , thalidomide dexamethasone , second year maintenance therapy consist dexamethasone . - The novel agent thalidomide bortezomib introduce upfront , transplantation maintenance .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Patients must diagnosis active MM require treatment . Patients previous history smolder myeloma eligible evidence progressive disease require chemotherapy . 2 . Protein criterion must present ( quantifiable Mcomponent IgG , IgA , IgD , IgE and/or urinary kappa lambda light chain , BenceJones protein , Free Kappa Light Chain Free Lambda Light Chain ) order evaluate response . Nonsecretory patient eligible provided patient &gt; 20 % plasmacytosis OR multiple ( &gt; 3 ) focal plasmacytoma focal lesion MRI . 3 . Patients must receive 12 month prior chemotherapy disease . Patients may receive prior radiotherapy provide approval obtain Principal Investigator . 4 . Patients must 1875 year age time initial registration . 5 . Ejection fraction ECHO MUGA â‰¥ 40 % perform within 60 day prior registration . 6 . Patients must adequate pulmonary function study &gt; 50 % predict mechanical aspect ( FEV1 , FVC ) diffusion capacity ( DLCO ) &gt; 50 % predict , within 60 day registration . If patient unable complete pulmonary function test due MM relate pain condition , exception may grant principal investigator document patient candidate high dose therapy . 7 . Patients must creatinine &lt; 3 mg/dl creatinine clearance &gt; 30mL/min 8 . Patients must performance status 02 base SWOG criterion . Patients poor performance status ( 34 ) , base solely bone pain eligible . 9 . All patient must inform investigational nature study must sign IRBapproved informed consent accordance institutional federal guideline . 1 . Platelet count &lt; 30 x 109/L , unless myelomarelated . 2 . Greater grade 2 peripheral neuropathy . 3 . Hypersensitivity bortezomib , boron , mannitol . 4 . Uncontrolled diabetes . 5 . Recent ( &lt; 6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrhythmia . 6 . Evidence chronic obstructive chronic restrictive pulmonary disease . 7 . Patients must light chain deposition diseaserelated renal failure creatinine &gt; 3 mg/dl . 8 . Patients must prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient receive treatment one year prior enrollment . Other cancer acceptable patient 's life expectancy exceed five year . 9 . Patients must significant comorbid medical condition uncontrolled life threaten infection . 10 . Pregnant nursing woman . Women childbearing potential must negative pregnancy test document within one week registration . Women men reproductive potential may participate unless agree use effective contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>myeloma</keyword>
</DOC>